Schnitzer Steel Industries Inc

Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.  The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.  Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.  Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Schnitzer Steel Reports Q3 Loss, Focuses on Strategic Growth

Schnitzer Steel is navigating a challenging market landscape with strategic initiatives aimed at improving margins and capitalizing on favorable demand trends. The company is focused on cost control, productivity improvements, and strategic investments to position itself for recovery and growth in a transitioning industry.

Schnitzer Steel Industries Inc doubles EBITDA in Q4 2024

Schnitzer Steel Industries Inc delivered a robust performance in Q4 2024, driven by increased sales volumes and cost-saving initiatives amidst challenging market conditions.
The company showcased strengths in managing operational efficiency, capitalizing on favorable market trends, and maintaining financial flexibility with manageable debt levels.
While facing challenges such as market headwinds and high capital expenditures, Schnitzer Steel has opportunities to further enhance operational efficiency, capitalize on market trends, and drive revenue growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Radius Recycling, Inc. engages in the recycling of ferrous and nonferrous scrap metal and manufacture of finished steel products. The company was founded by Sam Schnitzer in 1906 and is headquartered in Portland, OR.

Radius Health, Inc.'s (RDUS) CEO Kelly Martin on Q2 2020 Results - Earnings Call Transcript

Radius Health (RDUS) delivered earnings and revenue surprises of -15.85% and 3.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Radius Health (RDUS) Reports Q2 Loss, Tops Revenue Estimates

  Shares of Radius Health (NASDAQ:RDUS) rose 1.4% in pre-market trading after the company reported Q2 results.

Radius Health: Q2 Earnings Insights

WALTHAM, Mass., Aug.  10, 2020  (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced the appointment of Sean Murphy to its Board of Directors with immediate effect.

Sean Murphy joins Radius Health Board of Directors

Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Radius Health (RDUS) to Report a Decline in Earnings: What to Look Out for

WALTHAM, Mass., July  27, 2020  (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Monday, August 10, 2020. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide a company update.

Radius Health to Announce Second Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Monday, August 10, 2020

WALTHAM, Mass. and FLORENCE, Italy, July  23, 2020  (GLOBE NEWSWIRE) -- The Menarini Group and Radius Health, Inc. (Nasdaq: RDUS) announced today that the companies have entered into an exclusive global license agreement for development and commercialization of elacestrant.  

Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization of Elacestrant

Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock?

Why Is Radius Health (RDUS) Down 11.6% Since Last Earnings Report?

Radius partner Teijin Pharma has submitted a New Drug Application  for abaloparatide-SC for treatment of osteoporosis in Japan  

Pivotal Phase III trial of abaloparatide-SC in Japanese women and men with osteoporosis achieves primary endpoint

Radius Health, Inc. (RDUS) CEO Kelly Martin on Q1 2020 Results - Earnings Call Transcript

Radius (RDUS) reports wider-than-expected loss but beats sales estimates in the first quarter. The company lowers guidance for 2020.

Radius' (RDUS) Q1 Earnings Miss Estimates, Sales Surpass

Radius Health (RDUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Radius Health (RDUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

WALTHAM, Mass., April  28, 2020  (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Company’s Board of Directors (the “Board”) granted G. Kelly Martin, in connection with his appointment as Chief Executive Officer and President of the Company, an option (the “Time-Based Option”) to purchase 575,000 shares of the Company’s common stock with a per share exercise price of $16.46 (the “Exercise Price”), the closing trading price of the Company’s common stock on the Nasdaq Global Market on the grant date of April 28, 2020 (the “Grant Date”).  The Time-Based Option vests 25% on the first anniversary of the Grant Date, with the remaining 75% to vest in substantially equal monthly installments over the three years thereafter, subject to continued service with the Company through the applicable vesting dates, and has a ten-year term. 

Radius Health Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jesper Hoeiland to step down as President and Chief Executive Officer in order to return to Denmark with his family

Radius Health Announces CEO Leadership Transition

Radius Health (RDUS) Down 33.3% Since Last Earnings Report: Can It Rebound?

Radius (RDUS) reports narrower-than-expected loss and beats sales estimates in the fourth quarter of 2019 as Tymlos gains traction.

Radius (RDUS) Q4 Earnings Beat Estimates on Tymlos Strength

Radius Health, Inc. (RDUS) CEO Jesper Høiland on Q4 2019 Results - Earnings Call Transcript

Radius Health (RDUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Radius Health (RDUS) This Earnings Season?

Earnings Preview: Radius Health (RDUS) Q4 Earnings Expected to Decline

Radius Health, Inc. (RDUS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Moving Average Crossover Alert: Radius Health

Radius Health has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Radius Health Is in Oversold Territory: What???s Next?

Alector Inc

Amgen

Fulcrum Therapeutics Inc

Ultragenyx Pharmaceutical

SAGE Therapeutics

Sarepta Therapeutics

Vertex Pharmaceuticals

Biotech investing is risk-fraught, but for investors who make the right bets, the returns can be staggering.

8 Biotech Stocks Morgan Stanley Recommends For 2020

Why Is Radius Health (RDUS) Down 6.9% Since Last Earnings Report?

WALTHAM, Mass., Dec.  02, 2019  (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Compensation Committee of the Company’s Board of Directors granted a new employee an option to purchase 50,000 shares of the Company’s common stock with a per share exercise price of $ 21.76, the closing trading price of the Company’s common stock on the NASDAQ Global Market on the grant date of December 2, 2019.  The stock option vests 25% on the first anniversary of the grant date, with the remaining 75% to vest in monthly installments over the three years thereafter, subject to continued service with the Company through the applicable vesting dates, and has a ten-year term.  The stock option was granted as an inducement material to the employee entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).

Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Radius (RDUS) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019 as Tymlos gains traction.

News for Schnitzer Steel Industries Inc Stock (RDUS)